03 February 2014
BASEL, January 29. /ITAR-TASS/. Russia ranks second by the pharmaceutical market of over-the-counter medications, goes a report of the multinational pharmaceutical corporation Novartis.
According to the statements, the country became the world's second largest market and the strongest driver in this segment with its “double-digit growth” of over-the-counter drug sales.
As for the brands popular in Russia, Novartis cites anti-inflammatory drug Voltaren, nasal spray Otrivin and cold symptom-fighting powder Theraflu. Growth in sales of the two latter drugs increased due to cold winter, Novartis explains.
2013 financial statements came out on Wednesday showing Novartis’ revenue 2.2% up to 57.92 billion. Net profit declined 1% to 9.3 billion.
The company does not disclose over-the-counter sales summing the figure up with revenue from veterinary drugs. Sales in the segment grew 8.8% to 4.06 billion in 2013.
Novartis International AG set up in 1996 is Europe’s second pharmaceutical producer by market share with 120,000 employees operating in 140 countries. In Russia, Novartis has three kinds of businesses: over-the-counter medications, contact lenses and veterinary drugs
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024